insitro Revenue and Competitors
Estimated Revenue & Valuation
- insitro's estimated annual revenue is currently $69M per year.
- insitro's estimated revenue per employee is $217,000
- insitro's total funding is $743M.
Employee Data
- insitro has 318 Employees.
- insitro grew their employee count by 19% last year.
insitro's People
Name | Title | Email/Phone |
---|---|---|
1 | Founder and CEO | Reveal Email/Phone |
2 | CSO insitro | Reveal Email/Phone |
3 | CFO & CBO | Reveal Email/Phone |
4 | Head Statistical Genetics | Reveal Email/Phone |
5 | Head FP&A | Reveal Email/Phone |
6 | Head Information Technology | Reveal Email/Phone |
7 | Head Technology Partnerships; Corporate Development & Strategy Team | Reveal Email/Phone |
8 | SVP, Accounting & Financial Operations | Reveal Email/Phone |
9 | Associate Director, Administration | Executive Assistant to the CEO | Reveal Email/Phone |
10 | Director, Legal | Reveal Email/Phone |
insitro Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $2M | 20 | N/A | N/A | N/A |
What Is insitro?
insitro is a data-driven drug discovery and development company that leverages machine learning and high-throughput biology to transform the way medicines are created to help patients. At insitro, we are rethinking the entire drug discovery process, from the perspective of machine learning, human genetics, and high-throughput, quantitative biology. Over the past five decades, we have seen the development of new medicines becoming increasingly more difficult and expensive, leaving many patients with significant unmet need. Weᅢᄁ¬ツᆲ¬トᄁre embarking on a new approach to drug development ᅢᄁ¬ツᆲ¬タワ one that leverages machine learning and unique in vitro strategies for modeling disease state and designing new therapeutic interventions. We aim to eliminate key bottlenecks in traditional drug discovery, so we can help more people sooner and at a much lower cost to the patient and the healthcare industry. We believe that by harnessing the power of technology to interrogate and measure human biology, we can have a major impact on many diseases. We invest heavily in cutting edge bioengineering technologies to enable the construction of large-scale, high-quality data sets that are designed specifically to drive machine learning methods. Our first application is to use human genetics, functional genomics, and machine learning to build a new generation of in vitro human cell-derived disease models whose response to perturbation is designed to be predictive of human clinical outcomes. This cannot be done without great people. We are bringing together an outstanding team of people whose expertise spans multiple disciplines - life sciences, machine learning, human genetics, engineering, and drug discovery - and building a unique culture where people from diverse backgrounds work as a single team towards a common goal. We offer opportunities to collaborative people with expertise in life science and computational science. Join us to help bring better health to more people, faster and cheaper.
keywords:N/A$743M
Total Funding
318
Number of Employees
$69M
Revenue (est)
19%
Employee Growth %
N/A
Valuation
N/A
Accelerator
insitro News
In Part Three of this series on AI in Drug Discovery, Daphne Koller PhD, CEO and co-founder of insitro, discusses the application of AI to a...
insitro is a data-driven drug discovery and development company using machine learning and data at scale to transform the way that drugs are...
US-based Insitro, a drug discovery and development startup that utilizes machine learning and biology to transform drug discovery, raised US$ 400M in a Series C funding round on 15 March 2021. Investors: The funding round was led by Canada Pension Plan Investment Board (CPP Investments), with p ...
Insitro has raised a $400 million Series C led by Canada Pension Plan Investment Board, with participation from investors including Andreessen Horowitz, Casdin Capital, HOF Capital, Two Sigma Ventures, Temasek and Arch Venture Partners. The South San Francisco-based company uses machine learning ...
The artificial intelligence-powered drug discovery company insitro has secured a mammoth funding round of $400 million, to carry forward its development efforts and Big Pharma partnerships with the likes of Gilead and Bristol Myers Squibb. “For insitro, 2020 was a year of incredible growth and ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $71.8M | 331 | 5% | $306M |
#2 | $127.9M | 379 | 10% | N/A |
#3 | $130.6M | 387 | N/A | N/A |
#4 | $12.8M | 403 | -5% | $59.3M |
#5 | $35M | 421 | 5% | N/A |